Become a Member | Print Page | Contact Us | Report Abuse | Sign In
News & Press: News

ITOG Board of Directors Announces a New International Board Member

Friday, October 11, 2019   (0 Comments)
Posted by: Judy Dallas
Share |
ITOG is pleased to announce that Dr. Sophie Leboulleux has been elected as the newest international member of the ITOG Board of Directors. Sophie Leboulleux is board certified in endocrinology, nuclear medicine and oncology. She works in the Department of Nuclear Medicine and Endocrine Oncology in Villejuif, France where she is responsible for the Thyroid Cancer Multidisciplinary Team. Her current clinical interests include treatment and follow up of thyroid cancer from thyroid nodule to radioactive iodine refractory thyroid cancer and imaging of cancer with TEP. Her current research is focused on the role of adjuvant radioactive treatment administration and on radioactive refractory thyroid cancer. She leads a prospective randomized study on the utility of postoperative radioactive iodine treatment, a prospective study on redifferentiation and has been co-investigator for trials in radioactive iodine refractory differentiated thyroid cancer and medullary thyroid cancer. She is Associate Professor, Chief of the Department of Nuclear Medicine in Villejuif and Associate Professor in the Department of Endocrine Oncology. ITOG is fortunate to have such qualified individuals to serve on the board of directors, ensuring commitment to the mission of ITOG in catalyzing effective treatments for thyroid cancer. The Board of Directors would like to extend its thanks to Cosimo Durante, MD, PhD University of Rome, Sapienza, Rome, Italy and Christine Spitzweg, MD, University Hospital Munich, Ludwig-Maximilians-University, Munich for standing for election, their level of commitment to ITOG is remarkable and is a source of inspiration for all.

Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495

614-293-9779

Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.